Norges Bank’s IO Biotech IOBT Stock Holding History

Norges Bank’s Portfolio IOBT Stock Details IOBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,000	Closed	-$133K	–	2110
2022 Q1	$133K	Hold	25,000	–	–	﹤0.01%	2152
2021 Q4	$164K	Buy	+25,000	New	+$241K	﹤0.01%	2196

Other funds holding IOBT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Norges Bank's IOBT Position: Q2 2022 in Review

Norges Bank sold out of IO Biotech (IOBT) in Q2 2022, closing a stake of 25,000 shares — an estimated $133K sold.

Norges Bank first reported a position in IOBT in Q4 2021 and held it in 2 quarters. The position peaked at $164K in Q4 2021. 18 funds tracked by Wall St. Rank hold IOBT as of Q2 2022.

Norges Bank reported no remaining IO Biotech position as of Q2 2022 after selling out during the quarter.
Norges Bank sold 25,000 IO Biotech shares in Q2 2022, an estimated $133K.
Norges Bank first reported a position in IO Biotech in Q4 2021 and held it in 2 quarters.
Norges Bank's IO Biotech position peaked at $164K in Q4 2021.
18 funds tracked by Wall St. Rank held IO Biotech as of Q2 2022.

Based on Norges Bank's 13F filing for Q2 2022, filed 11 Aug 2022.